Cutaneous T-cell lymphoma in the setting of anti-tumor necrosis factor and immunomodulator therapy: A case report and literature review

James Dotimas¹, Manjusha Das² and Daniel Martin²

Abstract
Immunosuppressive therapy is well recognized as increasing the risk of lymphoma. Mycosis fungoides is a rare cutaneous form of T-cell lymphoma with a largely unknown etiology and not typically associated with immunosuppression. In this article, we describe our encounter with a 24-year-old male with Crohn’s disease in remission on immunotherapy, specifically dual therapy with azathioprine and infliximab, presenting with a facial rash found to be consistent with mycosis fungoides on biopsy. The patient’s rash resolved with treatment of topical steroids. In addition, the decision was made to discontinue his azathioprine to minimize his risks of developing future malignancies.

Keywords
Inflammatory bowel disease, immunotherapy, Crohn’s disease, lymphoma, mycosis fungoides

Date received: 15 January 2020; accepted: 31 May 2020

Introduction
Medical therapy to treat symptomatic Crohn’s disease has advanced over the past decade, due to the development of biologic and immunomodulator drugs. Crohn’s disease affects an estimated 3.2 per 1000 people in North America and has been increasing in incidence since the 1990s,¹ likely due to increased detection rates. Due to the progressive nature of the disease, those with Crohn’s disease have a slightly reduced life expectancy² because of the increased risk of malignancies.³ Crohn’s disease has a relapsing and remitting nature; therefore, proactive monitoring and escalating treatment as necessary is recommended. Once remission is achieved, relapse should be prevented with continuing medical therapy.⁴ Current data suggest treatment Crohn’s disease with dual immunomodulator therapy, such as the combination of azathioprine and infliximab, is more effective than monotherapy in preventing relapse.⁵,⁶ Despite improvements in medical therapy, an estimated 70% of patients with Crohn’s disease will require some type of surgery to relieve their symptoms.⁶

The immunosuppressive therapies available to manage Crohn’s disease include immunomodulators, such as azathioprine and methotrexate, and anti-tumor necrosis factor (TNF) agents, such as infliximab and adalimumab.⁷,⁸ Given the long-term use of immunosuppressive drugs in patients with Crohn’s, potential side effects should be proactively monitored and addressed. Adverse effects of these drugs include pancreatitis, myelosuppression, nausea, opportunistic infections, and hepatotoxicity.⁸ Several studies suggest an increased risk of malignancy, particularly both non-Hodgkin- and Hodgkin-type lymphomas in patients with inflammatory bowel disease (IBD) who are treated with thiopurines.⁹–¹³ In addition, this risk appears to increase gradually with continued use of azathioprine.¹⁴

Based on a meta-analysis by Kandiel et al.,¹⁵ the number needed to harm to cause a case of lymphoma in patients treated with either azathioprine or 6-mercaptopurine was estimated to be 4357 for patients aged 20–29 years and 355 for patients aged 70–79 years. Other studies have found an association between azathioprine use and an increased

---

¹The University of Illinois College of Medicine at Peoria, Peoria, IL, USA
²Division of Gastroenterology and Hepatology, Department of Internal Medicine, The University of Illinois College of Medicine at Peoria, Peoria, IL, USA

Corresponding Author: James Dotimas, The University of Illinois College of Medicine at Peoria, 1 Illini Drive, Peoria, IL 61605-2576, USA.
Email: jdotim2@uiuc.edu
incidence of other cancers, including nonmelanoma skin cancer and cutaneous squamous cell carcinoma. In addition, one case report describes a case of cutaneous mycosis fungoides in a patient with IBD treated with infliximab. Whether the increased risk of malignancy is due to the underlying inflammatory nature of Crohn’s disease or medication side effects remains unclear.

Case

A 24-year-old Caucasian male with ileocolonic Crohn’s disease presented for follow-up at the gastroenterology clinic for a progressively worsening facial rash. He had a history of complicated Crohn’s disease with perianal involvement requiring surgery but was in remission for the previous 2 years. He initially started treatment for Crohn’s disease with 2-month taper of prednisone as well as azathioprine and eventually bridged to infliximab after cessation of prednisone. His regimen at the time of the initial visit included azathioprine 200 mg daily and infliximab 5 mg/kg every 8 weeks. About a year after starting treatment, he had thiopurine metabolites measured, which were within normal limits, and he had no evidence of toxicity.

He sought medical attention 4 months prior to presentation at the dermatology clinic for the rash, which was exfoliative and initially unilateral on the malar surface of one cheek. He was given oral antibiotics for a presumed skin infection but returned to the clinic a few days later once the rash started to spread to the other side of his face. He reported significant sunlight exposure due to his work as a landscaper. He denied any other skin lesions or any musculoskeletal complaints. He also reported no gastrointestinal symptoms related to his Crohn’s disease. A punch biopsy was performed and sent to the Mayo Clinic Laboratory. Prior to receiving the final biopsy report, he was given a topical steroid ointment by the dermatology clinic and noticed resolution of the skin rash in 3 days without any reoccurrence since then. At the time of this visit, his C-reactive protein (CRP) was 0.24 mg/dL, erythrocyte sedimentation rate (ESR) 2 mm/h, rheumatoid factor < 15 IU/mL, and anti-nuclear antibody (ANA) negative. Other recent laboratory studies, including complete blood count (CBC) and comprehensive metabolic panel (CMP), were unremarkable.

The final pathology report, available at the time of our office visit, described “atypical, superficial dermal lymphoid infiltrate with epidermotropism, consistent with mycosis fungoides.” The risk of cutaneous lymphoma and other cancers while using immunomodulators was discussed with the patient. As he had significant risk factors, such as his age, race, and occupation, the decision was made to discontinue azathioprine. It was also recommended to continue treatment with infliximab to maintain remission of his Crohn’s disease. He was also educated about routine sun protection and close follow-up with dermatology in order to prevent his skin rash from reoccurring and monitor for new skin lesions.

Discussion/Conclusion

Mycosis fungoides is the most common form of cutaneous T-cell lymphoma, and it appears to be notably more common in males than females with an average age of onset between ages 45 and 55. The cause of mycosis fungoides remains unknown; however, current hypotheses include genetic abnormalities and environmental exposures. There have been reported cases of human T-lymphotropic virus type I in the peripheral blood or cutaneous lesions of some patients with mycosis fungoides, although its role in the pathogenesis of the disease remains controversial. It has been noted that the progression of mycosis fungoides involves progression of immunodeficiency to avoid antitumor immunity, indicating that the disease may be more prevalent in those with immunocompromised states.

The use of immunosuppressive drugs for IBD has allowed for better rates of remission. However, one of the challenges in managing patients with IBD is balancing the benefits and risks of medical therapy. Due to the nature of these drugs, chronic use of immunosuppressive medications enables tumor cells to proliferate. In particular, azathioprine and other thiopurine analogues inhibit lymphocyte proliferation and cytotoxic T-cell and natural killer cell function, preventing cell-mediated immunosurveillance of cancers.

There have been several studies examining the risk of lymphoma in IBD patients treated with thiopurine analogues. A meta-analysis performed by Kandiel et al. pooled six single-center studies and obtained a standardized incidence ratio of 4.18 for lymphoma in patients with IBD treated with thiopurines. The CESAME cohort study demonstrated that patients on combination thiopurine and anti-TNF therapy had a markedly elevated risk of lymphoma, with a calculated standardized incidence ratio of 10.2 of lymphoma in patients on dual immunosuppressive therapy. Therefore, there is a significant increased risk of cutaneous lymphomas in young, Caucasian males on dual immunosuppressive therapy for Crohn’s disease such as our patient.

Given the increased risk of lymphomas with dual immunosuppressive therapy, it was decided to discontinue azathioprine and continue infliximab monotherapy for maintenance therapy. Although the rash resolved with the use of topical steroids, our patient would be predisposed to developing other skin lesions especially given his occupational risk factor.

As dual therapy with anti-TNF and immunomodulators is considered mainstay for initial treatment of Crohn’s disease, consideration should be given for potential risks. Further examination of the association of immunosuppressive drugs and lymphoma is necessary to fully elucidate this risk for patients. All treatment risks need to be weighed against the impact of untreated IBD and the benefit these therapies can offer.

Acknowledgements

This study was carried out in accordance with the Declaration of Helsinki.
Author contributions
J.D. and M.D. wrote the manuscript and reviewed the literature. D.M. reviewed the literature and made critical revisions to the manuscript.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval
Our institution does not require ethical approval for reporting individual cases or case series.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The author would like to acknowledge the Research Open Access Publishing (ROAAP) Fund of the University of Illinois at Chicago for financial support towards the open access publishing fee for this article.

Guarantor
J.D. is the guarantor of this article.

Informed consent
Written informed consent was obtained from the patient for her anonymized information to be published in this article.

ORCID iD
James Dotimas https://orcid.org/0000-0002-6494-3265

References
1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142(1): 46–54.
2. Baumgart DC and Sandborn WJ. Crohn’s disease. Lancet 2012; 380(9853): 1590–1605.
3. Freeman HJ. Colorectal cancer risk in Crohn’s disease. World J Gastroenterol 2008; 14(12): 1810–1811.
4. Hanauer SB and Sandborn W. Practice parameters committee of the American College of G. Management of Crohn’s disease in adults. Am J Gastroenterol 2001; 96(3): 635–643.
5. Ruffolo C, Scarpa M and Bassi N. Infliximab, azathioprine, or combination therapy for Crohn’s disease. New Eng J Med 2010;363(11):1086–1087.
6. Latella G, Caprilli R and Travis S. In favour of early surgery in individual cases or case series. J Crohns Colitis 2011; 5(1): 1–4.
7. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60(5): 571–607.
8. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 2018; 113(4): 481–517.
9. Li S and Borowitz MJ. Primary Epstein-Barr virus-associated Hodgkin disease of the ileum complicating Crohn disease. Arch Pathol Lab Med 2001; 125(3): 424–427.
10. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122(1): 72–77.
11. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374(9701): 1617–1625.
12. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 2015; 13(5): 847–858.
13. Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017; 318(17): 1679–1686.
14. Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology 2013; 145(5): 1007–1015.
15. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54(8): 1121–1125.
16. Abbas AM, Almukhtar RM, Loftus EV, et al. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol 2014; 109(11): 1781–1793.
17. Inman GJ, Wang J, Nagano A, et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. Nature Communications 2018; 9(1): 3667.
18. Ganzetti G, Molinelli E, Campanati A, et al. Mycosis fungoides-like eruption and infliximab. J Clin Gastroenterol 2016; 50(7): 610–611.
19. Korgavkar K, Xiong M and Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol 2013; 149(11): 1295–1299.
20. Whittaker S. Biological insights into the pathogenesis of cutaneous T-cell lymphomas (CTCL). Semi Oncol 2006; 33(1, Suppl. 3): S3–S6.
21. Wong HK, Mishra A, Hake T, et al. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 2011; 155(2): 150–166.
22. Pancake BA, Zucker-Franklin D and Coutavas EE. The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients. J Clin Invest 1995; 95(2): 547–554.
23. Krejsgaard T, Odum N, Geisler C, et al. Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome. Leukemia 2012; 26(3): 424–432.
24. Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016; 91(1): 151–165.
25. Fraser AG, Orchard TR and Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50(4): 485–489.
26. Bewtra M and Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol 2010; 6(4): 621–631.